EPS for Intersect ENT, Inc. (XENT) Expected At $-0.17; Stelliam Investment Management LP Lowered Aetna New (AET) Stake By $23.06 Million

February 15, 2018 - By Winifred Garcia

Stelliam Investment Management Lp decreased Aetna Inc New (AET) stake by 29.59% reported in 2017Q3 SEC filing. Stelliam Investment Management Lp sold 145,000 shares as Aetna Inc New (AET)’s stock rose 12.84%. The Stelliam Investment Management Lp holds 345,000 shares with $54.86 million value, down from 490,000 last quarter. Aetna Inc New now has $57.77 billion valuation. The stock decreased 0.98% or $1.75 during the last trading session, reaching $176.77. About 1.91M shares traded. Aetna Inc. (NYSE:AET) has risen 28.84% since February 15, 2017 and is uptrending. It has outperformed by 12.14% the S&P500.

Analysts expect Intersect ENT, Inc. (NASDAQ:XENT) to report $-0.17 EPS on February, 27.They anticipate $0.00 EPS change or 0.00% from last quarter’s $-0.17 EPS. After having $-0.15 EPS previously, Intersect ENT, Inc.’s analysts see 13.33% EPS growth. The stock increased 1.75% or $0.625 during the last trading session, reaching $36.425. About 225,694 shares traded. Intersect ENT, Inc. (NASDAQ:XENT) has risen 79.98% since February 15, 2017 and is uptrending. It has outperformed by 63.28% the S&P500.

Investors sentiment increased to 0.91 in 2017 Q3. Its up 0.22, from 0.69 in 2017Q2. It increased, as 42 investors sold AET shares while 302 reduced holdings. 80 funds opened positions while 232 raised stakes. 281.08 million shares or 3.09% less from 290.06 million shares in 2017Q2 were reported. Ledyard Natl Bank, New Hampshire-based fund reported 897 shares. Sandy Spring National Bank & Trust invested in 508 shares or 0.01% of the stock. Old Mutual Customised Solutions (Proprietary) Ltd invested in 0.14% or 6,703 shares. Parkside Finance Natl Bank Trust reported 326 shares. Guggenheim Lc holds 0.17% of its portfolio in Aetna Inc. (NYSE:AET) for 445,086 shares. Tiedemann Wealth Mngmt Limited Com reported 0.04% in Aetna Inc. (NYSE:AET). American Century Companies Inc reported 164,413 shares. Amer Service Incorporated has invested 1% in Aetna Inc. (NYSE:AET). Moors Cabot Inc holds 2,384 shares or 0.05% of its portfolio. Churchill Mgmt owns 18,148 shares or 0.07% of their US portfolio. Moreover, Loring Wolcott & Coolidge Fiduciary Advsrs Llp Ma has 0% invested in Aetna Inc. (NYSE:AET) for 26 shares. Proshare Advisors Limited Liability Corporation accumulated 37,739 shares or 0.06% of the stock. Lingohr Partner Asset Management Gmbh holds 0.93% or 10,600 shares in its portfolio. Citigroup has invested 0.04% in Aetna Inc. (NYSE:AET). 45,808 are held by Daiwa Secs Grp.

Since September 15, 2017, it had 0 buys, and 2 insider sales for $4.15 million activity. Lynch Karen S had sold 15,271 shares worth $2.47 million on Monday, September 18. McCarthy Margaret M had sold 10,288 shares worth $1.68 million.

Stelliam Investment Management Lp increased Southwestern Energy Co (NYSE:SWN) stake by 3.40 million shares to 12.58M valued at $76.85M in 2017Q3. It also upped Chesapeake Energy Corp (NYSE:CHK) stake by 122,500 shares and now owns 7.60M shares. Range Res Corp (NYSE:RRC) was raised too.

Among 24 analysts covering Aetna (NYSE:AET), 11 have Buy rating, 0 Sell and 13 Hold. Therefore 46% are positive. Aetna had 72 analyst reports since July 30, 2015 according to SRatingsIntel. On Monday, December 18 the stock rating was maintained by Wells Fargo with “Buy”. As per Friday, October 27, the company rating was downgraded by Cantor Fitzgerald. RBC Capital Markets maintained the stock with “Outperform” rating in Friday, June 9 report. As per Thursday, July 13, the company rating was maintained by Credit Suisse. The rating was maintained by Cantor Fitzgerald with “Hold” on Tuesday, January 30. Jefferies maintained Aetna Inc. (NYSE:AET) on Friday, January 12 with “Hold” rating. The rating was maintained by Cowen & Co on Tuesday, January 30 with “Buy”. On Tuesday, February 2 the stock rating was maintained by RBC Capital Markets with “Outperform”. The firm has “Hold” rating given on Tuesday, January 30 by Jefferies. RBC Capital Markets maintained the stock with “Buy” rating in Monday, October 9 report.

Intersect ENT, Inc., a commercial stage drug-device company, provides therapeutic solutions for patients with ear, nose, and throat conditions in the United States. The company has market cap of $1.07 billion. It offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It currently has negative earnings. The firm is also developing RESOLVE, a steroid releasing implant for refractory disease for the treatment of patients in the physician office setting.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: